Request for Proposals: Efficacy of Lebrikizumab in patients with fibrosing skin conditions
Eli Lilly and Company invites research proposals studying how lebrikizumab works in treating fibrosing skin conditions to advance clinical and scientific understanding.
Funder: Eli Lilly and Company
Due Dates (Anticipated): February 2027
Funding Amounts: Funding and/or study drug support; amount and duration vary by proposal.
Summary: Supports investigator-initiated research on the efficacy of lebrikizumab in fibrosing skin conditions.
Key Information: This is a forecasted opportunity—dates and requirements may shift; check the program page for updates.
Description
This opportunity, offered by Eli Lilly and Company, invites external researchers to submit proposals investigating the efficacy and mechanisms of lebrikizumab in the treatment of fibrosing skin conditions. The initiative aims to advance understanding of clinical benefits and inform dermatological practice. Selected projects will be reviewed by Lilly’s global medical and scientific committees to ensure alignment with current scientific priorities and the potential to contribute valuable insights to the field.
